Rating: Neutral | Target Price: RMB 23.5–25.4 (base-case fair value range) | Current Price: RMB 22.75 (A-share, close on 2026-10-27) | Margin of Safety: ~3% (vs. lower bound of base-case range) | Probability-Weighted Expected Return: ~+6.9% | Time Horizon: 12 months
Report Date: 2026-10-27 | Total share capital 2.670 billion shares (A-shares 2.118 billion + H-shares 552 million), corresponding to total market cap of ~RMB 60.75 billion | H-share HK$16.43 ≈ RMB 13.96, A/H premium 62.9%
Fosun Pharma's conclusion can be summarized in one sentence: the transformation is real, earnings have not yet caught up, and the price is not expensive but not cheap enough to ignore quality issues. The evidence on the revenue side is solid—FY2025 innovative drug revenue of RMB 9.893 billion (+29.59%), accounting for 23.7% of group revenue; 9M2026 grew another 15.54%; overseas revenue share rose to 30.96%; BD deals are moving from one-off transactions to framework agreements (up to 10 biosimilars to Sandoz). However, profit realization lags behind—core net profit has been flat for three years (RMB 2.011 → 2.314 → 2.340 billion); headline profit growth relies on disposal gains and fair value changes (non-recurring items accounted for 36.1% of attributable profit in 9M26); and free cash flow turned negative again. On valuation, PB of 1.25x sits at the 1st percentile of the past 10 years, but this largely reflects a rational repricing of a lower ROE center (~7%) rather than mispricing; on a core-earnings basis, 26x is not cheap. The base-case fair value of RMB 23.5–25.4 is only ~3%–12% above the current price, leaving a thin margin of safety—and two binary events lie ahead: the November 2026 medical insurance/commercial insurance dual-directory negotiations and the Q4 showdown against equity incentive targets (requiring a single-quarter RMB 1.293 billion, +52.5% YoY). This report assigns a Neutral rating: do not chase at current levels; wait for validation. Under the same thesis, the H-share, at a 38.6% discount (with a HK$1.0 billion buyback providing a floor), offers better risk-reward than the A-share. The core constraints are earnings quality, minority-interest dilution, and the "Fosun group" credit discount; the core options are innovative drug volume ramp-up, monetization of the BD platform, and the re-rating potential from incentive target achievement.
Nature of the opportunity: conditional opportunity, evidence grade B. Catalysts over the next 12–18 months are dense and verifiable: announcement of the medical insurance/commercial insurance "dual directory" results in late November 2026 (the biggest policy variable for Q4); the January–March 2027 annual results showdown against equity incentive targets (attributable profit of RMB 3.96 billion, innovative drug revenue of RMB 11.23 billion); signing of the first formal agreements with Sandoz and receipt of upfront payments (2026 invoicing cap of USD 100.5 million ≈ RMB 670 million, converted at the frozen rate of 6.6676); continued execution of the HK$1.0 billion H-share buyback (~HK$194 million executed so far); and a trend decline in the controlling shareholder's pledge ratio since September 2026 (balance of 555 million shares; the company has stated there are no further pledge plans).
The primary share price driver is the degree of achievement of equity incentive targets: the market currently assigns only 12.7–13.4x forward PE to the 2027 attributable profit target of RMB 4.77 billion (peer 2025 static median 30.6x), so success or failure will directly determine the pricing of "transformation credibility." There are two verifiable expectation gaps: first, the H-share trades at a ~38.6% discount on identical fundamentals (A/H premium 62.9%; note that the premium has widened from ~43% over the past 14 months, with no evidence yet of convergence); second, progress against the innovative drug revenue target line (implied +13.5% for 2026) is on track (9M26 already +15.54%), in contrast to the difficulty of hitting the attributable profit line. One caveat: sell-side coverage is extremely thin (only 3–4 firms, no consensus target price, flat estimate revisions over 90 days), so the sample basis for "market expectations" is limited. Falsification points: core products suffering price cuts exceeding 25% in national reimbursement negotiations or failing renewal; Q4 attributable profit falling significantly below RMB 1.29 billion; narrowing margin of safety in the Gland asset group's goodwill impairment test. In the four-dimensional assessment (change/driver/expectation gap/catalysts), the expectation gap dimension is neutral-to-weak, while the others are moderate-to-strong.
Key evidence:
Three qualifications must be emphasized. First, Sandoz's USD 322 million is a "maximum" cap; actual 2026 invoicing will not exceed ~RMB 670 million, and this occurs at the Henlius level (minority shareholders hold ~40%), so the attributable profit uplift is far smaller than the invoicing amount itself. Second, innovative drug revenue growth decelerated from +29.59% to +15.54%, and the overseas figure does not strip out FX effects (group-wide constant-currency revenue growth of 5.81% vs. nominal 3.64%). Third, profits have not kept pace: 9M26 innovation-related R&D investment rose sharply, and revenue-mix improvement is being eaten up by accelerated R&D spending. This thesis therefore supports "eligibility for a valuation re-rating," not "a re-rating that has already happened."
Key evidence:
Two fairness notes: a high non-recurring share has been a multi-year reporting norm for Fosun (37.7% in 9M25) and does not constitute evidence of "deterioration," but it is sufficient to explain the valuation discount. The logical relationship between the attributable profit and innovative drug revenue targets in the incentive plan (and/or) was not verified in these materials—if an alternative path exists, the "low probability of achievement" statement needs revision; but regardless of the terms, sell-side consensus being below the target itself shows the market is not pricing for achievement. The R&D capitalization ratio for FY2023–2025 was 26.8%/34.4%/32.1%; on an income-statement basis, 9M26 has risen to ~40%. Capitalization is providing increasing "help" to core earnings—another layer of discount on earnings quality.
Key evidence:
Goodwill, development expenditure, and intangible assets total ~RMB 33.69 billion, or ~67% of attributable net assets—a structural basis for amplification in bear markets. But objectively: FY2025 goodwill impairment was zero (the RMB 688 million impairment provision is entirely legacy stock) and 9M26 total impairments were only RMB 88 million; risk exposure is concentrated in the single Gland asset group. US injectable price erosion or an FDA compliance event is the main trigger (there were media reports that its India plant received an FDA Form 483 in October 2026, which could not be verified through official channels in this report and is not used as evidence). The price-sensitivity levels of the pledge chain are distant (warning/liquidation price levels estimated at ~RMB 10.8/8.8 based on September announcement data); the real transmission path is the refinancing environment at the Fosun International level, and the parent's H1 2026 return to profitability and deleveraging are marginal improvement signals.
Key evidence:
Two honest caveats on the valuation judgment. First, "63% of the current price is a growth option" is a definitional residual derived by backing out EPV—it could be the market paying for an option, or it could be rational pricing of a low-ROE, heavily diluted structure; this report cannot distinguish between the two and can only point out that realization depends on (Q4 non-recurring items, BD, incentive targets). Second, the A/H discount has widened over the past 14 months (~43% → 62.9%); the H-share buyback has executed only ~HK$194 million (~2% of H-share free-float market cap), so "discount convergence" is currently a hypothesis, not a trend. The judgment that the H-share is superior rests on the static depth of the discount and the existence of the buyback floor, not on convergence having occurred.
| Metric | FY2023 | FY2024 | FY2025 | 2026Q1–Q3 (Latest) |
|---|---|---|---|---|
| Revenue (RMB 100mn) | 414.00 | 410.67 | 416.62 | 304.63 |
| Revenue YoY | -5.81% | -0.80% | +1.45% | +3.64% |
| Attributable net profit (RMB 100mn) | 23.86 | 27.70 | 33.71 | 26.67 |
| Attributable YoY | -36.04% | +16.08% | +21.69% | +5.71% |
| Core net profit (RMB 100mn) | 20.11 | 23.14 | 23.40 | 17.06 |
| Core YoY | -48.08% | +15.10% | +1.12% | +8.42% |
| Gross margin | 47.84% | 47.97% | 50.07% | 49.71% |
| Attributable net margin | 5.76% | 6.74% | 8.09% | 8.76% |
| Operating cash flow (RMB 100mn) | 34.14 | 44.77 | 52.13 | 34.27 |
| Free cash flow (RMB 100mn, OCF − capex cash) | -19.22 | 0.67 | 7.65 | -8.39 |
| Total R&D investment (RMB 100mn) | 59.37 | 55.54 | 59.13 | 52.47 (+31.24%) |
| R&D capitalization ratio | 26.8% | 34.4% | 32.1% | ~40% (income-statement basis estimate) |
| Debt-to-asset ratio (period-end) | 50.10% | 48.98% | 48.49% | 47.89% |
Balance sheet and leverage (as of 2026-09-30, latest balance sheet basis): cash and equivalents RMB 13.297 billion + trading financial assets RMB 2.460 billion = cash-like assets RMB 15.757 billion; total interest-bearing debt RMB 41.182 billion (short-term borrowings 15.489 + non-current liabilities due within one year 7.468 + long-term borrowings 14.347 + bonds payable 1.100 + lease liabilities 2.778); net debt RMB 25.425 billion, net debt/EBITDA ~2.56x (based on FY2025 EBITDA of RMB 9.946 billion); goodwill RMB 10.760 billion, development expenditure RMB 8.484 billion, intangible assets RMB 14.443 billion.
Drivers of metric changes (YoY ≥ ±20% or structural anomalies, with company explanations):
2026 first three quarters: revenue RMB 30.463 billion (+3.64%), attributable net profit RMB 2.667 billion (+5.71%), core earnings RMB 1.706 billion (+8.42%), gross margin 49.71% (+1.51pp). Q3 single quarter: revenue RMB 10.021 billion (+1.44%), attributable profit RMB 946 million (+15.18%), core earnings RMB 562 million (-8.32%), operating cash flow RMB 1.003 billion (-19.60%). The divergence between single-quarter attributable and core earnings is explained quite clearly in the company's notes: out-licensing upfronts raised the base in the prior-year period, JV/associate gains/losses decreased, and FX losses increased; meanwhile, the strong attributable growth this quarter was mainly driven by fair value change gains (9M26 swung from -RMB 375 million a year ago to +RMB 484 million; non-recurring items totaled RMB 962 million, 36.1% of attributable profit). Structural trends remain positive: innovative drug revenue +15.54%, overseas share 30.96%, R&D investment +31.24% (innovative drug R&D at 82.83% of total); however, capex cash +34.65% and development expenditure +42.7% show that investment intensity has risen rather than fallen, and FCF turned negative again (9M26 -RMB 839 million).
Versus expectations: sell-side consensus for 2026E attributable profit is RMB 3.804–3.822 billion; 9M26 represents ~70% achievement. Q4 needs attributable profit of RMB 1.293 billion (vs. RMB 848 million a year ago, +52.5% YoY) to reach the RMB 3.96 billion incentive target—even counting Sandoz invoicing within the year (≤RMB 670 million, with attributable uplift far smaller) and year-end disposal capacity, achievement remains a low-probability event; the market is effectively anchored near RMB 3.8 billion. Judging whether this quarter "beat expectations" is constrained by the very thin coverage sample (3–4 firms), so no market conclusion is drawn here—only a reconciliation against management's stated metrics: progress on the innovative drug revenue target line (implied +13.5% for the full year) is on track, while the attributable profit target line is clearly lagging.
Business model snapshot: A diversified pharmaceutical group, with pharmaceuticals as the core business (71.6% of revenue: innovative drugs + biosimilars + high-end generics, with vertically integrated heparin APIs-to-formulations), supplemented by medical devices & diagnostics (10.4%) and healthcare services (17.7%, loss-making); the associate Sinopharm Group (equity method) contributed RMB 1.707 billion in investment income. Asset-heavy with high R&D investment; revenue is non-subscription-based with no recurring contractual income; strong bargaining power over upstream API suppliers (self-supplied), weak bargaining power over downstream payers (passive price cuts from centralized procurement/NRDL negotiations); gross margin improvement (48.0%→50.1%) is driven by the structural effect of a rising innovative drug mix, not price increases.
Cash content of earnings test: OCF/net profit attributable to parent has remained at 1.43/1.62/1.55 for consecutive years (1.28 in 9M26), indicating solid collection quality; but FCF/net profit attributable to parent is -0.81/0.02/0.23 (-0.31 in 9M26) — the bulk of book profits is converted into cash, only to be swallowed by capex and capitalized R&D; the long-term risk of FCF/net profit <0.5 must be explicitly flagged. Recurring earnings test: FY2025 net profit attributable to parent of RMB 3.371 billion vs. adjusted (recurring) profit of RMB 2.340 billion, a gap of RMB 1.030 billion (30.6%, ≥15% threshold) — roughly RMB 1 billion comes from disposal gains, fair value changes and government grants; core earnings are actually RMB 2.34 billion and have been flat for three years; the reported "high growth" is amplified by one-off items. The company does not disclose a Non-GAAP reconciliation; the adjusted (recurring) figure is the closest official measure.
Return on capital: This report estimates ROIC at approximately 5.2% (FY2025 NOPAT RMB 5.222 billion / invested capital RMB 99.933 billion), below the 8% warning line and significantly below the ~10% discount rate — incremental capital returns have not yet covered the cost of capital; the "pseudo-growth" warning signal is triggered, and this judgment needs to be hedged against the sustainability of innovative drug revenue scaling. ROE attributable to parent is approximately 7% (5.29%/5.90%/7.03% for 2023–2025), below Hengrui (14.26%) and Hansoh (17.54%).
Capex quality: On a cash basis, CapEx/depreciation was 1.39/1.19 for FY2024–2025; the company does not disclose a maintenance/growth split, so the level of maintenance investment cannot be determined. The 2025 annual report committed that "subsequent capital expenditure will focus on fixed asset optimization and maintenance, with investment intensity significantly reduced," but in 9M26 cash paid for asset purchases rose 34.65% and development expenditure rose 42.7% — actual execution runs opposite to the commitment (the increment is mainly capitalized R&D rather than capacity). This is a deviation in investment direction, not accounting fraud.
Moat and quality red flags: The genuine moat lies in global registration and manufacturing (17 workshops/production lines certified under US/EU/WHO GMP; serplulimab approved in 40+ countries/regions), CAR-T first-mover advantage and commercial insurance positioning (Yikaida included in the first commercial insurance innovative drug catalog; 210+ treatment centers), the full heparin value chain and artesunate WHO PQ, and channel synergies with Sinopharm. Red flags: non-recurring gains/losses have exceeded 30% of profit for multiple consecutive years; persistently weak FCF; minority interest income at 17.9% of net profit (RMB 580 million in 9M26) continuously diluting parent-attributable profit; goodwill + development expenditure + intangible assets at approximately 67% of net assets attributable to parent.
Say-do consistency: partially delivered, generally pragmatic, but with two deviations. Commitment vs. delivery reconciliation: ① Dividend commitment — "annual dividends no less than 30% of net profit attributable to parent since 2012"; actual payouts FY2023/2024/2025 were 30.25%/30.49%/30.54%, delivered; ② 2025 operating plan (efficiency gains, asset-lightening) — OCF +16.45%, debt-to-asset ratio down to 48.49, nearly RMB 3 billion recovered from non-core assets: largely delivered, though adjusted profit grew only +1.12%; ③ 2025 annual report's claim that "investment intensity will be significantly reduced" — 9M26 purchase cash +34.65%, development expenditure +42.7%: execution clearly deviates; ④ Shanghai Clone divestiture — deadline twice postponed to 2027-03-31, with breach-of-contract compensation clauses; delivery uncertain.
Shareholder friendliness: shareholder-friendly (relative to similar holding platforms). Stable payout ratio of 30%+ (FY2025: RMB 3.90 per 10 shares, cash dividends of RMB 1.029 billion, dividend yield of 1.70% at current price); ~RMB 390 million in combined A+H buybacks in 2025 with partial A-share cancellation; in August 2026, a new H-share buyback of up to HK$1 billion launched (HK$194 million executed at an average price of HK$17.08); no record of share issuance/rights-issue dilution (option and RSU reserves are small). Note: the dividend base includes one-off gains on a parent-attributable basis; the effective payout ratio on an adjusted basis is higher (approximately 44%), and the sustainability of cash dividends depends on disposal proceeds.
Risk signals: Controlling shareholder Fosun High-Tech has 555 million shares pledged, or 57.73% of its holdings (twice released in October — marginal improvement but still high in absolute terms); Co-President Zhang Wenjie (formerly head of the innovative drug business unit and Henlius) resigned on 2026-09-30; key-person changes in the innovative drug line warrant monitoring; related-party sales of RMB 6.156 billion, or 14.78% of revenue (mainly flowing to the associate Sinopharm Group system); multiple announcements of related-party loan renewals.
| Segment (FY2025) | Revenue (RMB 100M) | Share | Gross Margin | YoY | Segment Profit | Business Logic in One Line |
|---|---|---|---|---|---|---|
| Pharmaceuticals | 298.33 | 71.61% | 57.39% (+3.09pp) | +3.14% | RMB 4.022B (78.7% of total profit) | Profit engine: innovative drug ramp + biosimilar going global + full heparin chain |
| Medical Devices & Diagnostics | 43.21 | 10.37% | 50.45% (+0.37pp) | -0.05% | RMB 82M (turnaround) | da Vinci distribution/medical aesthetics/ventilators; profitability just recovering |
| Healthcare Services | 76.47 | 17.70% | 20.71% (-2.00pp) | -3.58% | -RMB 216M (2026H1 loss of -RMB 207M nearly equals full-year) | 19 hospitals + 24 rehabilitation hospitals in ramp-up; heavy fixed costs |
| Sinopharm Group (associate, equity method) | — | — | — | Revenue +3.94% | Investment income RMB 1.707B (33% of total profit) | Second profit pillar; channel synergy |
The profit engine is the pharmaceutical segment — 71.6% of revenue × 57.4% gross margin, contributing nearly 80% of total profit; but the parent-attributable figure is diluted by minority interests in Henlius (2025 revenue RMB 6.667 billion, net profit RMB 827 million, minorities holding ~40%) and Gland (stake reduced to 45.76%); the gap between consolidated reported profit and parent-attributable distributable profit is widening (minority interests rose from RMB 13.099B to 15.769B within six months). The gross margin structure gap is 36.7pp (pharma 57.4% vs. healthcare services 20.7%) and must be highlighted: the former is a patent/registration-barrier business, the latter an asset-heavy, regional, reimbursement-priced hospital business — fundamentally two different businesses, which is also the micro-level source of the "conglomerate discount." The healthcare services segment's 2026H1 loss is already close to the FY2025 full-year figure; loss reduction progress is the key segment-level watch item.
Accounting red flags (by severity):
Cross-period consistency:
Current market data and percentiles: A-share close at RMB 22.75 (2026-10-27), total market cap of RMB 60.75 billion; PE(TTM) 17.3x (6th percentile over 5 years), PB 1.25x (1st percentile over 10 years; 10-year low of 1.21x), PS(TTM) 1.43x, dividend yield 1.70%. Percentiles are for reference only: the company is in a high-R&D-investment phase and TTM parent-attributable profit includes RMB 962 million of non-recurring items; mechanical percentiles would understate true expensiveness — 26.0x on an adjusted basis is the proper reference for sustainable earnings, and a substantial part of the "1st-percentile PB" is a rational repricing of the ROE center falling from historical levels to approximately 7%. Average daily turnover of approximately RMB 350–450 million (0.6–0.7% of market cap); liquidity is normal; no low-liquidity warning needed.
| Peer Comparison (close of 2026-10-27) | 2025 Static PE | PB | 2025 Revenue Growth | ROE | Notes |
|---|---|---|---|---|---|
| Hengrui Medicine | 39.2x | 5.66x | +13.0% | 14.3% | Pure innovation benchmark; innovative drugs at 58% of drug sales |
| Sino Biopharmaceutical | 32.6x | 2.44x | +10.3% | 7.5% (adjusted PE ~17x) | Most comparable generic-to-innovation transition; innovation share 47.8% |
| Hansoh Pharmaceutical | 28.7x | 4.98x | +22.6% | 17.3% | Net margin 37% post generic runoff; a completed transition case |
| CSPC Pharmaceutical | 20.3x | 2.41x | -10.4% | 11.9% | Mirror image of key patent expiry + procurement pain |
| Fosun Pharma | 18.0x (adjusted 26.0x) | 1.25x | +1.45% | ~7.0% | Cheapest on the surface, not cheap on an adjusted basis |
Market-implied expectations: RMB 60.75 billion market cap = 18.0x FY2025 parent-attributable profit = 26.0x FY2025 adjusted profit = 16.0x 2026E consensus = 13.4x 2027E = 12.7x 2027 incentive target. In one line: the current price assumes Fosun stays at near-zero growth on 2025 profit levels, whereas reality is revenue +3.6%/innovative drugs +15.5%, adjusted profit +8.4% — the market gives the transition significantly less credit than peers (peer static median 30.6x; comparable transition company Sino Biopharm at ~17x adjusted), but most of the discount can be explained by adjusted/parent-attributable at only 70%, ROE of 7%, minority dilution, and the holding structure. The implied expectation is judged as "slightly pessimistic, broadly reasonable."
Three-tier value (EPV): Zero-growth EPV of RMB 8.33/share (sustainable FCFE of approximately RMB 2.23 billion ÷ cost of equity 10%: adjusted basis ×0.9 cash conversion factor, this report's estimate; discount rate includes ~1pct premium for leverage/goodwill/governance). Asset value floor: listed tradable equity stakes — ~63% of Henlius ≈ RMB 14.9B + 45.76% of Gland Pharma ≈ RMB 16.0–17.2B (range between sell-down transaction anchor and market cap anchor) + indirect stake in Sinopharm Group (49%×55.52%, chain to be verified) ≈ RMB 11.1B, totaling approximately RMB 42.0–43.3B; less net debt of RMB 22.65B ≈ RMB 19.4–20.6B, or RMB 7.2–7.7/share (broad measure; consolidated cash overlap not excluded). About 63% of the current price is supported by growth options (EPV share approximately 37%) — this is not "the market pricing only for zero growth" (quite the opposite: the market is paying a large option premium); option payoffs depend on Q4 non-recurring items, BD deals landing, and incentive targets being met — the largest source of variance in the valuation distribution.
Three scenarios and odds:
| Scenario | Probability | Fair Range | Key Driver | vs. Current Price |
|---|---|---|---|---|
| Bear | 30% | RMB 18–20 | Core NRDL-negotiated product price cuts >25%/renewal failure + impairment of RMB 1–2B; 2026 parent-attributable profit falls back to ~RMB 3.4B, incentive targets missed; growth options repriced | -21% ~ -12% (midpoint RMB 19: -16.5%) |
| Base | 50% | RMB 23.5–25.4 | 2026 parent-attributable ~RMB 3.8B (near consensus, slightly below target) × 16.5–17x; 2027E RMB 4.5B × 14.5–15x; innovative drug revenue RMB 11.23→13.48B delivering in transit | +3% ~ +12% (midpoint RMB 24.45: +7.5%) |
| Bull | 20% | RMB 30–34 | US$1B-scale BD deal total consideration realized + 2027 incentive target of RMB 4.77B met × 17–19x + independent re-rating of innovative drugs | +32% ~ +49% (midpoint RMB 32: +40.7%) |
Basis for anchoring the base-case exit multiple: ~45% discount to the peer 2025 static median of 30.6x (corresponding to a triple discount for earnings quality/minority dilution/holding structure), ~15–18% discount to CSPC's 20.3x — the anchor is independent of the company's current multiple (18x shown for reference only). External benchmarks: Morgan Stanley set A-shares at RMB 40 / H-shares at HK$32 in 2026-04 (prior to Q3 adjusted profit turning negative; not adopted); Capital Securities maintained H-shares "Buy" in 2026-10 with a target of HK$21. Probability-weighted expectation of approximately RMB 24.3 (+6.9%); margin of safety (base-case floor of RMB 23.5 vs. current price) of approximately 3.3% — thin.
House earnings forecast (anchor for next results reconciliation):
| Period | Revenue | Parent-attributable Net Profit | Adjusted | Key Assumptions |
|---|---|---|---|---|
| FY2026E | RMB 41.8–42.5B | RMB 3.65–3.95B (midpoint 3.80) | RMB 2.3–2.5B | Innovative drug revenue ≈ RMB 11.2B (+13.5%); Sandoz invoicing ≤ RMB 670M; Q4 parent-attributable depends on non-recurring items; NRDL negotiations and 12th batch procurement price cuts as headwinds |
| FY2027E | RMB 43.5–45.2B | RMB 4.3–4.7B (midpoint 4.5) | RMB 2.6–3.0B | Innovative drug revenue targeting RMB 13.48B (+20%); procurement base cleared; recurring milestones and overseas supply ramp-up; healthcare services loss reduction |
Three-way reconciliation: Management incentive targets (RMB 3.96/4.77B) > this report's midpoints (RMB 3.80/4.5B) ≈ sell-side consensus (RMB 3.804–3.822/4.52B). This report does not treat "approximately RMB 800 million per year of recurring licensing income" (Morgan Stanley's measure) as an independent incremental in the base case — that forecast is already embedded in their revenue upgrade, avoiding double counting.
Conclusion: degree of undervaluation judged as "reasonably inexpensive" — quality and price assessed separately: quality is a middling business mid-transition (ROIC 5.2%, weak FCF, heavy dilution); price is near the lower end of the base-case fair range, slightly below the reasonable midpoint. The A-shares currently offer no meaningful margin of safety for entry; until catalysts are verified (Q4 parent-attributable profit, NRDL negotiation results, Sandoz proceeds), "cheap" alone is not a reason to buy. The H-shares trade at a 38.6% discount on the same fundamentals, plus support from the HK$1 billion buyback — a better expression of the same thesis (H-share free-float market cap of only ~HK$9.1B, so transaction costs are higher than A-shares).
Industry size. China's pharmaceutical industry (above designated size) posted 2025 revenue of RMB 2,956.25 billion (-0.6%) and profit of RMB 408.0 billion (+1.4%) (China Pharmaceutical Enterprises Association, 2026-04); the National Bureau of Statistics' pharmaceutical manufacturing category recorded 2025 total profit of RMB 349.0 billion (+2.7%). The industry is in a phase of "bottoming out in volume, profit turning positive" — generics rising in volume but falling in price drag on revenue, while innovative drugs structurally scale up and support profit. Innovative drug submarket: approximately USD 159.2 billion in 2024 (Frost & Sullivan basis, ~15% of global); KPMG forecasts a 2023–2030 CAGR of about 11.3% for China's innovative drug market. Drivers: aging population (323 million people aged 60+ at end-2025, 23.0% of total) + payment expansion (dual catalog of basic medical insurance + commercial insurance) + outbound BD deals.
Value chain and value distribution. APIs (upstream, fragmented, weak bargaining power) → pharmaceuticals (thickest-margin segment) → distribution/hospitals (dominated by giants such as Sinopharm) → medical insurance payment (ultimate payer, strongest bargaining power). Fosun is a rare full-value-chain player in the A-share market: vertical integration of heparin from "crude material to API to formulation" reduces costs; pharma gross margin of 57.4% is being lifted by innovative drug mix; downstream, its associate Sinopharm (2025 revenue of RMB 584.5 billion, net profit attributable to parent of RMB 7.05 billion, contributing ~RMB 1.7 billion of investment income to Fosun) locks in the main distribution channel. Gross profit mainly accrues in pharma manufacturing, but pricing power rests with payers — an industry-wide constraint. Fosun partially circumvents single-payer price pressure via 31% overseas revenue and the commercial insurance catalog (Yifkaida/CAR-T included in the first commercial innovative drug catalog).
Supply, demand, and competitive landscape. Demand side: aging and rigid expansion of oncology/chronic disease penetration; commercial insurance opens a new payment layer for high-priced innovative drugs. Supply side: generic overcapacity being cleared via centralized procurement (the 11th round drew 794 product bids from 445 companies, far more intense competition than the prior ten rounds); innovative drugs face homogeneous involution, yet assets are being repriced globally — in 2025, China's innovative drugs logged 157 outbound BD deals totaling USD 135.655 billion (+161% YoY) with USD 7 billion in upfront payments; in H1 2026, license-out deal value reached approximately USD 110 billion, about 80% of the full-year 2025 total (PharmCube). This is essentially an arbitrage window of "China R&D costs + global pricing," with MNCs' reliance on in-licensing structurally rising. Concentration: the top 100 pharma industrial companies posted combined 2025 revenue of ~RMB 1,000.2 billion, ~33.8% of the industry; the top three are Sinopharm Group, China Resources Pharmaceutical, and Qilu Pharmaceutical; innovative drugs show a "Hengrui as the dominant player + multiple strong players including Sino Pharma/CSPC/Hansoh/Fosun" pattern. Entry barriers: innovative drugs require capital (Fosun's 2025 R&D spending of RMB 5.913 billion) plus global regulatory/clinical capabilities; generics require consistency evaluation + procurement access + API integration.
Cycle and regulation. The industry is transitioning from the 2021–2025 "procurement + cost control" downcycle into a policy bottom and structural transformation period: the 11th national procurement round implemented in Feb–Mar 2026 (anti-involution rules: anchor pricing, revival mechanism); the 12th round opened bids on 7-31 (65 products; the company won 4, management deems the impact manageable); the 2025 NRDL added 114 items (including 50 Class 1 innovative drugs); the first commercial innovative drug catalog of 19 products (including 5 CAR-Ts) took effect 2026-01-01; the 2026 dual-catalog adjustment plan was released in late May, introducing "pre-application" for the first time, with results to be announced before end-November — we are currently in the policy window ahead of the negotiation results. Direction: continued headwind for legacy generics (permanent downward shift of the profit-margin ceiling), clear tailwinds for innovative drugs/CAR-T/outbound licensing.
Quantified chain of the demand inflection (industry-level repricing). Driver: MNC spending on acquiring Chinese pipelines (USD 51.9 billion in 2024 → USD 135.655 billion in 2025); step-up in per-deal value: Fosun's 2025 GLP-1 licensing to Pfizer carried a USD 150 million upfront and USD 1.935 billion in potential milestones — upgrading from "selling products" to "selling pipelines"; penetration ramp: industry BD deal value started small in 2023 (Simcere–Pfizer USD 1.25 billion upfront) → exploded in 2025 → sustaining a steep trajectory into 2026. Fosun's position: per company disclosure, 7 out-licensing/co-development deals in 2025 with combined upfronts of USD 261 million (from the 2025 annual report investor presentation; not independently verified deal by deal in this report; the verifiable large deal is Pfizer's USD 150 million upfront), roughly 3.7% of industry upfronts — right direction, small share, trailing Hengrui/Hansoh's large single-deal licenses. Differentiation lies in "two-way licensing" (in-licending Ocandyz/Dazifei etc. + out-licensing GLP-1/CD38 etc.) and global regulatory/manufacturing capability (registrations across China, US, and Europe; Perjeta biosimilar approved in 50+ countries/regions).
Peer benchmarking and company positioning. See Section IX benchmark table. Fosun is one of the largest comprehensive A+H pharma platforms by revenue (RMB 41.662 billion vs Hengrui RMB 31.6 billion, Sino Pharma RMB 31.8 billion, CSPC RMB 26.0 billion, Hansoh RMB 15.0 billion), but it is positioned as a platform-based chaser rather than an innovation-purity leader: innovative drugs account for 23.7% of group revenue (Hengrui 58.34%, Hansoh 82.2%, Sino Pharma 47.8%), ROE ~7% (Hengrui 14.26%, Hansoh 17.54%). The transformation path is quantitatively anchored: equity incentives set an innovative drug revenue CAGR of ~16.7% for 2025–2027 (RMB 9.893 → 13.48 billion) and attributable net profit CAGR of ~20%. Share trend: amid flat core pharma revenue, the innovative drug share rises ~6.8pp annually, while legacy generics are continuously repriced by procurement. Moat sources: global registration and manufacturing, CAR-T first-mover advantage + commercial insurance positioning, full-chain heparin and artesunate WHO PQ (40 specifications, cumulative supply of 440 million doses globally), Sinopharm channel + da Vinci surgical robot (500+ installed) platform synergies. Key drags: minority-interest dilution, Gland stake reduced to 45.76%, healthcare services losses. Methodology note: industry rankings cited in the annual report (e.g., "one of the largest comprehensive platforms by revenue") reflect association/company disclosures; innovative drug share and ROE are estimated in this report from financial statements — the two bases do not conflict.
The decisive battlegrounds for pharma lie not in generic financial frameworks but in three areas: procurement exposure, pipeline delivery, and BD monetization capability.
Procurement exposure (legacy repricing): Since the 4+7 expansion through the 11th round, the company has cumulatively won ~48 products in national procurement. A representative case: febuxostat (Uriritong) posted domestic sales of ~RMB 1.126 billion in 2019; after winning the 3rd procurement round, daily medication cost fell to ~RMB 1.3, a ~90% price cut; in 2025 it remains a top-ten single formulation product but at a much-reduced scale — a mirror image of "price down, volume up." Current exposure: in the 11th round (implemented 2026-02), the company won 6 products (including two newly acquired heavyweight generics, roxadustat and nintedanib, with volume growth and price cuts landing simultaneously in 2026–2027); in the 12th round (bids opened 2026-07-31), the company won 4 products. Buffers: the heparin franchise has full-chain crude-to-API-to-formulation cost advantages and US/EU exports diversify risk; revenue in procurement-sensitive areas such as anti-infection/metabolism/CNS already declined in 2025 (-5.63%/-6.95%/-8.98%), with mainland pharma revenue at -3.64% — repricing exposure for legacy generics persists, but the marginal impact is narrowing (newly won products are mostly newly approved incremental ones; anti-involution rules).
Key innovation pipeline milestones (as of end-Q3 2026): Approved — Vekatu (BCMA×CD3, third-line relapsed/refractory multiple myeloma, conditional approval); Fumaining (MEK inhibitor) added adult NF1 plexiform neurofibromatosis indication (covering all age groups); Under review — HLX14 denosumab (60mg and 120mg strengths; the originator posted global 2025 sales of USD 8.092 billion; already approved in US/EU/UK/Canada; potential first-wave domestic approval); Clinical — HLX43 (PD-L1 ADC) Phase II initiated; FXR0906 (APOC3 siRNA) and two other INDs approved; Filed — second CAR-T brexucabtagene autoleucel (r/r B-ALL, accepted by NMPA). CAR-T payment: Yifkaida included in the first commercial innovative drug catalog (19 products including 5 CAR-Ts), covered by 110+ Huimin Bao plans, 210+ accredited treatment centers.
Two-way BD monetization: Outbound (license-out) — Pfizer GLP-1 (USD 150 million upfront received); Sandoz biosimilar framework (up to 10 products, first batch up to USD 322 million, invoicing ≤USD 100.5 million in 2026); Eisai's Japan rights for Hansizhuang (USD 75 million upfront + milestones totaling over USD 380 million, signed early 2026); Inbound (license-in) — two TCEs from Amberstone's T-MATE platform (upfront ≤USD 4 million + milestones up to USD 884 million). Assessment: Fosun's BD is shifting from "one-off single deals" to "framework-based batches," but its upfront scale (~USD 261 million in 2025, ~3.7% industry share) is not yet sufficient to independently justify a valuation re-rating — BD is an option; realization depends on subsequent Sandoz batch-by-batch signings and milestone inflows.
Rating: Neutral; confidence 0.50; horizon 12 months. Overall judgment: the current price of RMB 22.75 is near the lower end of the base fair value range (RMB 23.5–25.4), with a probability-weighted expected return of about +6.9% and a safety margin of ~3% — the odds are symmetric-to-positive but not fat; quality (ROIC 5.2%, flat recurring earnings, heavy dilution) does not support "buy because it's cheap," and two binary events — the November dual-catalog negotiation and the Q4 attributable profit test — lie ahead. Strategy: do not chase at the current price; if the A-share pulls back to RMB 20–21 (upper edge of the bear case) without damage to the fundamental thesis, the risk-reward improves materially; under the same logic, the H-share (38.6% discount + HKD 1 billion buyback) is the better expression, but requires accepting the H-share's small float and entry/exit costs. Upside triggers: Sandoz first batch received + mild national negotiation + Q4 attributable profit beat → recovery toward the upper edge of the base case or even the bull case; downside triggers: negotiation price cut exceeding 25% + impairment booked → toward the bear case of RMB 18–20.
Key risks: ① Controlling shareholder pledge and Fosun International credit transmission (warning/forced-liquidation levels of ~RMB 10.8/8.8; price triggers are distant, but the refinancing environment is a precondition); ② earnings quality: Q4 attributable profit needs +52.5% to hit target; a miss would pull the earnings anchor back to the recurring-profit midpoint; ③ impairment chain of RMB 10.76 billion goodwill (Gland safety margin 12.5%) and RMB 8.48 billion development expenditure; ④ 12th-round procurement implementation and 2026 national negotiation price cuts (Hansizhuang 2026H1 revenue -3.4% due to price cuts, per earnings call); ⑤ FX and OCI erosion (9M26 attributable OCI of -RMB 845 million).
Monitoring calendar (next 12 months):
Data and methodology notes: All prices and market capitalizations in this report are anchored to the 2026-10-27 A-share close of RMB 22.75; FX rates HKD/CNY 0.84996, USD/CNY 6.6676 (2026-10-27). Financial data are as of the 2026 Q3 report (balance sheet date 2026-09-30; the Q3 report was disclosed on Juchao on 2026-10-28). Percentile figures are computed by our tools. This report is independent research and does not constitute investment advice.